ATE404669T1 - In brust- und blasenkrebs differentiell exprimiertes gen und durch dieses kodierte polypeptide - Google Patents

In brust- und blasenkrebs differentiell exprimiertes gen und durch dieses kodierte polypeptide

Info

Publication number
ATE404669T1
ATE404669T1 AT01926595T AT01926595T ATE404669T1 AT E404669 T1 ATE404669 T1 AT E404669T1 AT 01926595 T AT01926595 T AT 01926595T AT 01926595 T AT01926595 T AT 01926595T AT E404669 T1 ATE404669 T1 AT E404669T1
Authority
AT
Austria
Prior art keywords
differentially expressed
breast
bladder cancer
polypeptides encoded
present
Prior art date
Application number
AT01926595T
Other languages
German (de)
English (en)
Inventor
Maurice Zauderer
Elizabeth Evans
Melinda Borrello
Original Assignee
Univ Rochester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Rochester filed Critical Univ Rochester
Application granted granted Critical
Publication of ATE404669T1 publication Critical patent/ATE404669T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT01926595T 2000-04-04 2001-04-04 In brust- und blasenkrebs differentiell exprimiertes gen und durch dieses kodierte polypeptide ATE404669T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US19446300P 2000-04-04 2000-04-04

Publications (1)

Publication Number Publication Date
ATE404669T1 true ATE404669T1 (de) 2008-08-15

Family

ID=22717696

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01926595T ATE404669T1 (de) 2000-04-04 2001-04-04 In brust- und blasenkrebs differentiell exprimiertes gen und durch dieses kodierte polypeptide

Country Status (10)

Country Link
US (3) US7268207B2 (https=)
EP (1) EP1272636B8 (https=)
JP (1) JP2004502408A (https=)
CN (2) CN1610743A (https=)
AT (1) ATE404669T1 (https=)
AU (2) AU5311901A (https=)
CA (1) CA2413211A1 (https=)
DE (1) DE60135315D1 (https=)
NZ (1) NZ522282A (https=)
WO (1) WO2001074859A2 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7268207B2 (en) * 2000-04-04 2007-09-11 University Of Rochester Gene differentially expressed in breast and bladder cancer, and encoded polypeptides
US7135278B1 (en) 2000-09-29 2006-11-14 University Of Rochester Method of screening for therapeutics for infectious diseases
JP2005503118A (ja) * 2001-02-14 2005-02-03 ジェンザイム・コーポレーション 改変ペプチドリガンド
WO2003004989A2 (en) * 2001-06-21 2003-01-16 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
WO2003104428A2 (en) * 2002-01-21 2003-12-18 Vaccinex, Inc. Gene differentially expressed in breast and bladder cancer and encoded polypeptides
US9809654B2 (en) 2002-09-27 2017-11-07 Vaccinex, Inc. Targeted CD1d molecules
WO2004087058A2 (en) * 2003-03-28 2004-10-14 Vaccinex, Inc. Targeted mhc class i alpha3 vaccine delivery systems
US20050042218A1 (en) * 2003-07-10 2005-02-24 Vaccinex, Inc. MHC class I - peptide-antibody conjugates with modified beta2-microglobulin
CA2548180C (en) * 2003-12-04 2014-02-04 Vaccinex, Inc. Methods of killing tumor cells by targeting internal antigens exposed on apoptotic tumor cells
US20050266425A1 (en) * 2003-12-31 2005-12-01 Vaccinex, Inc. Methods for producing and identifying multispecific antibodies
EP1756308A1 (en) * 2004-04-23 2007-02-28 Exagen Diagnostics, Inc. Compositions and methods for breast cancer prognosis
CA2656918A1 (en) * 2006-06-22 2007-12-27 Vaccinex, Inc. Anti-c35 antibodies for treating cancer
JP5357782B2 (ja) * 2007-02-21 2013-12-04 バクシネックス インコーポレーティッド 抗原負荷CD1d分子によるNKT細胞活性の調節
KR101666228B1 (ko) 2007-09-28 2016-10-13 인트렉손 코포레이션 생물치료학적 분자를 발현시키기 위한 치료학적 유전자-스위치 작제물 및 생물반응기, 및 이의 용도
NZ586544A (en) 2007-12-26 2012-07-27 Vaccinex Inc Anti-c35 antibody in combination with an ani-her2 antibody in cancer therapies and methods
DK2385980T3 (en) 2009-01-08 2018-07-30 Albert Einstein College Medicine Inc BACTERIA VACCINES WITH CELL-WALL-ASSOCIATED CERAMIDE-LIKE GLYCOLIPIDS AND APPLICATIONS THEREOF
CA2794577C (en) * 2009-04-01 2021-02-23 The University Of British Columbia Semaphorin 3c (sema3c) inhibitor therapeutics, methods, and uses
US8946379B2 (en) 2009-09-24 2015-02-03 The Regents Of The University Of California Bladder cancer specific ligand peptides
US9371352B2 (en) 2013-02-08 2016-06-21 Vaccinex, Inc. Modified glycolipids and methods of making and using the same
RU2729116C2 (ru) * 2015-12-16 2020-08-04 Гритстоун Онколоджи, Инк. Идентификация, производство и применение неоантигенов
JP7763588B2 (ja) * 2017-09-05 2025-11-04 グリットストーン バイオ インコーポレイテッド T細胞療法用の新生抗原の特定法
KR20260039788A (ko) 2017-10-10 2026-03-20 시애틀 프로젝트 코포레이션 핫스팟을 이용한 신생항원 동정
CA3083097A1 (en) 2017-11-22 2019-05-31 Gritstone Oncology, Inc. Reducing junction epitope presentation for neoantigens
KR20250162921A (ko) 2018-04-09 2025-11-19 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 계내 유전자 시퀀싱의 방법
KR102318018B1 (ko) 2019-07-05 2021-10-28 한국생산기술연구원 마이크로 제품 제작용 맨드렐 제작 방법, 마이크로 제품 제작용 몰드 제작 방법 및 마이크로 제품 제작용 몰드
WO2021076770A1 (en) * 2019-10-18 2021-04-22 The Board Of Trustees Of The Leland Stanford Junior University Clinical- and industrial-scale intact-tissue sequencing
CN115407064B (zh) * 2021-05-26 2025-09-23 复旦大学附属肿瘤医院 肿瘤干细胞血管拟态标志物tem8在制备诊断试剂和试剂盒中的用途
US20240409582A1 (en) * 2022-08-23 2024-12-12 The University of North Texas Health Sciences Cente Design and characterization of inhibitory peptides (ipeps) derived from of mien 1 protein sequence

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0581600A (ja) * 1991-04-18 1993-04-02 Fujitsu Ltd 双曲線航法システムにおけるシステム監視処理方式
AU4998993A (en) 1992-08-07 1994-03-03 Epimmune, Inc. Hla binding peptides and their uses
CN1118572A (zh) 1993-03-05 1996-03-13 萨依特尔有限公司 Hla-a2.1组合肽及其用途
US5856131A (en) * 1997-02-24 1999-01-05 Incyte Pharmaceuticals, Inc. Human selenoprotein
US7026447B2 (en) * 1997-10-09 2006-04-11 Human Genome Sciences, Inc. 53 human secreted proteins
CA2316397A1 (en) * 1997-12-24 1999-07-08 Corixa Corporation Compounds for immunotherapy and diagnosis of breast cancer and methods for their use
WO1999037775A2 (en) 1998-01-26 1999-07-29 Genquest, Inc. Compositions and methods for detecting and treating breast cancer
US6783961B1 (en) * 1999-02-26 2004-08-31 Genset S.A. Expressed sequence tags and encoded human proteins
CA2296792A1 (en) 1999-02-26 2000-08-26 Genset S.A. Expressed sequence tags and encoded human proteins
US20020052308A1 (en) * 1999-03-12 2002-05-02 Rosen Craig A. Nucleic acids, proteins and antibodies
AU3395900A (en) * 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
WO2001040269A2 (en) * 1999-11-30 2001-06-07 Corixa Corporation Compositions and methods for therapy and diagnosis of breast cancer
US7268207B2 (en) * 2000-04-04 2007-09-11 University Of Rochester Gene differentially expressed in breast and bladder cancer, and encoded polypeptides
US20030166277A1 (en) 2000-04-12 2003-09-04 University Of Rochester Targeted vaccine delivery systems
US20050196755A1 (en) * 2000-11-17 2005-09-08 Maurice Zauderer In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
EP1340088B1 (en) * 2000-11-17 2007-01-17 University Of Rochester In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
WO2003104428A2 (en) * 2002-01-21 2003-12-18 Vaccinex, Inc. Gene differentially expressed in breast and bladder cancer and encoded polypeptides
US20050042218A1 (en) 2003-07-10 2005-02-24 Vaccinex, Inc. MHC class I - peptide-antibody conjugates with modified beta2-microglobulin
CA2548180C (en) * 2003-12-04 2014-02-04 Vaccinex, Inc. Methods of killing tumor cells by targeting internal antigens exposed on apoptotic tumor cells

Also Published As

Publication number Publication date
AU2001253119B2 (en) 2006-04-13
CN1610743A (zh) 2005-04-27
DE60135315D1 (de) 2008-09-25
NZ522282A (en) 2005-03-24
JP2004502408A (ja) 2004-01-29
EP1272636B8 (en) 2008-10-08
US20090312263A1 (en) 2009-12-17
CN101643732A (zh) 2010-02-10
EP1272636B1 (en) 2008-08-13
US7910551B2 (en) 2011-03-22
CA2413211A1 (en) 2001-10-11
WO2001074859A3 (en) 2002-03-28
US20070081942A1 (en) 2007-04-12
US7268207B2 (en) 2007-09-11
AU5311901A (en) 2001-10-15
US20020155447A1 (en) 2002-10-24
WO2001074859A2 (en) 2001-10-11
EP1272636A2 (en) 2003-01-08

Similar Documents

Publication Publication Date Title
ATE404669T1 (de) In brust- und blasenkrebs differentiell exprimiertes gen und durch dieses kodierte polypeptide
HUP0302532A2 (hu) Petefészekrák terápiájában és diagnosztizálásában alkalmazható készítmények és eljárások
WO2002016413A8 (en) Cripto tumour polypeptide
TR200001646T2 (tr) Bir salgılanmış meme kanseri proteini olan mamaglobin.
WO2001057182A3 (en) Nucleic acids, proteins, and antibodies
PT1200590E (pt) Antigénio transmembranar lectina tipo c expresso em cancro da próstata humano e utilizações do mesmo
HRP20150432T1 (hr) Indentifikacija antigena povezanih s tumorom za dijagnozu i terapiju
IL149046A (en) Composition comprising a polynucleotide encoding a 36p6d5 polypeptide for use in diagnosing cancer and diagnostic method related to 36p6d5
TW200728465A (en) Compositions and methods for the therapy and diagnosis of prostate cancer
NZ330887A (en) Monoclonals and polyclonals antibodies for the diagnosis of breast cancer
AR031250A1 (es) Composiciones y metodos para la terapia y el diagnostico del cancer de pulmon
EP2070949A3 (en) Gene differentially expressed in breast and bladder cancer and encoded polypeptides
EA200970607A1 (ru) Универсальная вакцина из опухолевых клеток для противораковой терапии и профилактического использования
MX2021004425A (es) Vacuna contra cancer de cadena invariante de teleosteo.
WO1999051263A3 (en) Methods and modified cells for the treatment of cancer
WO2005053604A3 (en) Antibodies specific for cancer associated antigen sm5-1 and uses thereof
WO2001018046A3 (en) Ovarian tumor sequences and methods of use therefor
WO2003013431A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
WO2001090152A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
JP2005524719A5 (https=)
IL207012A0 (en) Diagnosis and therapy of cancer using sgp28-related molecules
ATE206129T1 (de) Herstellung und verwendung des menschlichen nm23- h2-proteins und dagegen gerichtete antikörper
WO2002066506A3 (en) Use of casb7439 (ash2) in the immunotherapy of breast cancer
WO2003024302A3 (en) Detection and treatment of cancers of breast
ATE373711T1 (de) Gewebe-spezifische protein 103p2d6, hochexprimiert in verschiedene krebsarten

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties